Identification of salivary volatile organic compounds as the potential diagnostic markers of oral cancer by the gas chromatography–mass spectrometry analysis

Sreekanth Puthuparambil Kunjumon[1,A,C], Sujatha S. Reddy[2,A], Pavan Kumar Tupakula[2,B], Shwetha Venkataramana[2,B], Haripriya Prathap[2,B], Ruchika Chaudhary[3,F], Vaishnavi Palanisamy[4,D], Laipubam Fabina Sharma[5,E]

[1] Department of Dentistry, Aster Whitefield Hospital, Bengaluru, India

[2] Department of Oral Medicine and Radiology, Faculty of Dental Sciences, M.S. Ramaiah University of Applied Sciences, Bengaluru, India

[3] Department of Oral Medicine and Radiology, Government Dental College and Hospital, Jaipur, India

[4] NJ Dental Space, Coimbatore, India

[5] Fabdontics Dental Care, Imphal, India

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;
D – writing the article; E – critical revision of the article; F – final approval of the article

Abstract

Background. Oral cancer (OC) is a major public health problem in the Indian subcontinent. As many as 90% of all OC cases are oral squamous cell carcinomas (OSCCs), often developing from oral potentially malignant disorders (OPMDs). Although the oral cavity is freely accessible, visual identification is often challenging. Biopsy and a microscopic examination is the only confirmatory diagnostic test. Recently, the analysis of volatile organic compounds (VOCs) has emerged as a new, non-invasive, rapid, and inexpensive strategy with promising potential in clinical diagnostics. The human VOCs produced in metabolic pathways, present in body fluids and the exhaled air, can be used for monitoring several oral diseases, including OC.

Objectives. The aim of the present study was to determine the potential diagnostic capabilities of salivary VOCs in OC through identifying and comparing the salivary volatilomic profiles among OSCC and OPMD subjects, as well as healthy controls, using the gas chromatography–mass spectrometry (GC–MS) analysis.

Material and methods. Unstimulated saliva samples were collected from 35 OSCC subjects, 35 OPMD subjects and 40 healthy controls. The VOCs extracted from the ZSM-5/PDMS film were condensed with 100 µL of methanol, of which 1.0 µL was subjected to the GC–MS analysis.

Results. A total of 128 salivary VOCs were detected and identified among the OSCC and OPMD subjects and the healthy controls. Twenty-five metabolites were determined to be statistically significant in differentiating among the 3 groups. Organic acids, alcohols, ketones, alkanes, and acid amides were the major classes of VOCs in the OSCC subjects, while organic acids, alcohols, ketones, acid amides, heterocyclic compounds, and phenols constituted the VOC profile in the OPMD subjects. 1-chloro-dodecane and 1-tridecanol were significant VOCs observed among the controls.

Conclusions. The study demonstrates that salivary VOC profiling can reveal distinct metabolomic alterations in OSCC and OPMDs, with several VOCs emerging as potential tumor-specific biomarkers. While these findings highlight the promise of VOC-based screening, larger studies are needed to validate these markers and establish their clinical applicability.

Keywords: GC–MS, OPMDs, oral cancer, salivary volatile organic compounds (VOCs), metabolomics

Highlights

- A volatile organic compound (VOC)-based metabolomic approach was utilized to profile patients with oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs) in comparison with healthy controls.
- Unique VOC patterns were observed in OSCC and OPMDs, even though both conditions shared similar compound classes.
- The VOC signatures showed significant correlations with key demographic factors, such as age, gender or tobacco use, and clinical factors, like the pTNM and histopathologicl staging.
- Several VOCs have emerged as potential tumor-specific biomarkers for the screening of OSCC and OPMDs, offering promising diagnostic applications.
- Larger, multicenter studies are required to validate these findings and facilitate the clinical implementation of VOC-based screening for OSCC and OPMDs.

Introduction

Head and neck squamous cell carcinoma (HNSCC) represents the 6th most common type of cancer worldwide, with India being considered the global capital for oral cancer (OC), posing a serious health challenge.[1–3] Among HNSCCs, oral squamous cell carcinoma (OSCC) arising from the mucosal surfaces of the oral cavity is the most common type, often preceded by oral potentially malignant disorders (OPMDs), such as oral leukoplakia (OL), oral submucous fibrosis (OSF), oral lichen planus (OLP), etc. Tobacco consumption, including smoked and smokeless tobacco (SLT) products, betel-quid chewing, excessive alcohol consumption, poor oral hygiene, nutrient-deficient diet, and sustained viral infections, e.g., human papillomavirus (HPV), are some of the risk factors associated with the development of OSCC. As compared to the West, the concern with regard to OSCC is significantly higher in India, where about 70% of cases are detected in the advanced stages of the disease, contributing to an increased mortality rate,[4] with the 5-year survival rates around 40%, despite advances in therapy. Hence, early diagnosis and treatment remain the key to improved patient survival.

Most of the research efforts today are focused on the prevention and early detection of the tumor. The visual and screening tests widely used for diagnosis include clinical methods, a cytopathology examination and visualization adjuncts, like tissue autofluorescence. However, the efficacy of these modalities is limited by gaps in the clinician's knowledge and experience, as well as the anatomical site being examined.[5] Although the histopathological examination has remained the gold standard for diagnosing oral dysplastic changes, it is invasive and often tedious to patients; moreover, early lesions of OSCC, including premalignant lesions, are subtle and rarely exhibit the clinical features observed in the established lesions. Hence, there is a high demand for simple, non-invasive and low-cost alternatives, along with a strong unmet need for novel diagnostic tools and prognostic determinants.

This underscores the importance of developing new methods for cancer detection.

Some of the approaches include genomics, proteomics and metabolomics. Amongst these, one of the most promising metabolomic approaches is that of volatile organic compounds (VOCs), a family of carbon-containing compounds. Volatile organic compounds cover a range of chemical classes, including aliphatic, aromatic and chlorinated hydrocarbons, aldehydes, ketones, esters, ethers, acids, and alcohols. They are supposed to serve as a potential and specific tool in early cancer detection in breath and body fluids, through the use of various analytical techniques, like gas chromatography–mass spectrometry (GC–MS). Such metabolic profiles act as chemical signatures, capable of characterizing specific processes in the organism, thereby potentially indicating pathologies like OSCC, OPMDs, and other biochemical disorders. During carcinogenesis, there is altered metabolism and upregulated aerobic glycolysis known as the Warburg effect, which induces oxidative stress.[6,7] This liberates highly reactive oxygen species (ROS) that induce the lipid peroxidation of (poly)unsaturated omega-3 and omega-6 fatty acids (PUFAs) in the cellular membranes, mostly generating alkanes and aldehydes as end-products. Considering the high number of hydrocarbons and aldehydes detected in several matrices, this plays a major role in HNSCC and, therefore, the compounds are biomarkers of interest.

Volatile organic compounds are considered potential biomarkers in non-invasive early cancer detection, as screening tools, especially for high-risk patients, e.g., smokers and heavy drinkers, and are also used for post-therapeutic monitoring for recurrence. They have already shown potential as biomarkers for lung, gastric, breast, and prostate cancer, and mesothelioma. Since carcinogenesis is related to inflammation and metabolic changes, VOCs may provide additional diagnostic value as biomarkers for OSCC. However, VOC expression in OSCC has been meagerly reported in the literature, and a major proportion of these studies have analyzed VOC biomarkers in breath. Hence, a substantial gap exists in the use

of salivary VOCs as the potential biomarkers of OSCC in clinical practices.

Saliva contains a wide range of analytes – hydrocarbons, proteins, peptides, hormones, gingival exudates, microbiota, and various small organic metabolites – that exhibit high responsiveness to physiological changes, making it a valuable biofluid for obtaining systemic information. Volatile organic compounds are transferred from blood to saliva, mainly via passive diffusion. Hence, salivary VOCs can reflect metabolic changes in response to degeneration, inflammation, necrosis, cancer, microbiota alteration, or external factors, such as environmental pollution, medication use and diet.[8] In addition, the use of saliva as a diagnostic tool for OSCC offers several advantages, including the ease of collection, non-invasiveness and cost-effective applicability for screening large populations. Moreover, dysplastic cells from the oral mucosa are continuously shed into saliva due to its close proximity to the epithelial surface. This facilitates the sampling of cells from occult sites, such as the tonsillar crypts, which are otherwise difficult to assess during a routine oral examination.

This study was undertaken to investigate OSCC- and OPMD-associated metabolic adaptations in cells, and to comparatively analyze salivary VOC profiles among OSCC patients, individuals with OPMD and healthy controls by identifying VOC alterations with the use of GC–MS.

Materials and methods

This is a cross-sectional study with 3 groups of participants: OSCC subjects (group 1); OPMD subjects (group 2); and healthy controls (group 3).

Study setting and ethical considerations

The study included OSCC, OPMD and healthy subjects reporting between January 2020 and October 2021 to the Department of Oral Medicine and Radiology and the Department of Surgical Oncology, M.S. Ramaiah Teaching Hospital, Bengaluru, India.

Ethical clearance was obtained from the Ethics Committee for Human Trials of M.S. Ramaiah University of Applied Sciences, Bengaluru, India (No. EC-2020/PG/36). Informed written consent was obtained from patients and controls after explaining the nature of the study. A total of 110 subjects were included in the study: 35 in group 1; 35 in group 2; and 40 in group 3.

Study participants

The inclusion criteria: patients aged >18 years; the histopathological confirmation of OSCC or OPMD; the absence of any treatment at the time of the study, includ-

ing surgery, chemotherapy or radiation; and good oral hygiene. Age and gender-matched control subjects: without a history of hypertension, diabetes or thyroid disorders, and the use of related medications; without any deleterious habits. The exclusion criteria: subjects with conditions affecting the quantity and quality of saliva (dry mouth, inflammatory and autoimmune salivary gland diseases, etc.).

Sample collection

Unstimulated saliva samples were collected between 8.00 a.m. and 11.00 a.m. (due to the circadian rhythm affecting the salivary flow). The subjects were asked to refrain from using alcohol, tobacco, food, and any oral hygiene products, such as toothpaste and mouthwash, 2 h prior to sample collection. Each subject was asked to thoroughly rinse their mouth with water. Unstimulated saliva (2 mL) was collected in a sterile 10-milliliter glass vial with a screw cap, immediately placed on dry ice in a cold storage box, and stored at −20°C until the pre-extraction process was performed. The collected samples were transported using the cold storage box to Wipro Food and Drug Laboratory, Bengaluru, India, for further processing and analysis. The process was repeated until a sample size of 100 was achieved.

Preparation of the ZSM 5/PDMS hybrid film

For the fabrication of the ZSM-5/PDMS hybrid film, a 50-milliliter glass bottle was used as the supporting substrate. The PDMS solution was prepared by mixing the base and the curing agent in a 10:1 ratio, and then blending it with ZSM-5 to obtain a 20 wt.% ZSM-5 mixture within the PDMS matrix prior to solidification. One gram of this mixture was placed in the glass bottle and kept at 25°C for 3 h, followed by heating at 100°C for 1 h. The resulting sample vials containing the ZSM-5/PDMS film were thoroughly rinsed with methanol and shaken at 120 rpm for 3 days to remove any unreacted PDMS monomers (Fig. 1).

Sample analysis

The 2 mL of the collected saliva sample was diluted with 1 mL of deionized water and added to the ZSM 5/PDMS hybrid film. The VOCs present in saliva were then extracted using a rotary shaker with a variable speed of 120 rpm by vigorously shaking the glass extraction bottle. The extraction container was carefully cleaned with pure water before being dried with liquid nitrogen. Finally, the VOCs extracted from the ZSM-5/PDMS film were condensed with 100 μL of methanol, of which 1.0 μL was subjected to the GC–MS analysis using a GC–MS machine (GCMS-QP2020 NX; Shimadzu, Kyoto, Japan) (Fig. 2).

Fig. 1. Steps in pre-extraction – preparation of the ZSM-5/PDMS film

Fig. 2. Pre-extraction followed by the gas chromatography–mass spectrometry (GC–MS) analysis
VOC – volatile organic compound.

GC–MS conditions

The GC–MS machine was used for the chromatographic analysis with mass spectrometric detection in the electron ionization mode at 70 eV. The interphase temperatures of the GC ion source were kept at 200°C and 230°C, respectively. Separation was accomplished using the HP-INNOWax capillary column (polyethylene glycol-based high-polarity stationary phase, length of 30 m, an inner diameter of 0.320 mm, film thickness of 0.25 m; 19091N-113I; Agilent, Santa Clara, USA). The mobile phase was 99.99% ultrahigh-quality helium gas, flowing at 1.78 mL/min. The temperature of the GC injection was fixed at 230°C. The oven temperature was set at 40°C for 3 min, then raised to 230°C at a rate of 10°C per minute for 5 min. The retention time data was recorded from 5 min 6 s to 27 min. Data acquisition was performed in the full scan mode with m/z = 35–500 and a scan time of 0.3 s. The mass spectrum library search program from the National Institute of Standards and Technology (NIST) (v. 2.3) was used to identify the sample chemicals. Compounds having a structural similarity score of over 700 were chosen as the validating biomarkers for successful VOC detection (Fig. 3).

Chromatogram WPG2108003 H:\2021\Aug 2021\06 aug\21080004-B2-OCS-1.qgd

Peak report TIC

| Peak No.	Retention time [min]	Area [a.u.]	Area [%]	Compound name
1.	12.027	42,520,515	40.40	acetic acid
2.	13.188	11,976,599	11.38	propanoic acid
3.	13.557	5,738,929	5.45	propanoic acid, 2-methyl-
4.	13.731	396,513	0.38	propylene glycol
5.	14.345	8,125,073	7.72	butanoic acid
6.	14.655	239,855	0.23	3-furanmethanol
7.	14.858	8,637,670	8.21	butanoic acid, 3-methyl-
8.	15.940	529,493	0.50	acetamide
9.	16.478	4,488,550	4.26	pentanoic acid, 4-methyl-
10.	16.580	1,369,028	1.30	butane, 1,4-bis(9,10-dihydro-9-methylanthracen-10-yl)-
11.	17.150	1,012,054	0.96	butane, 1,4-bis(9,10-dihydro-9-methylanthracen-10-yl)-
12.	18.784	393,645	0.37	phosphonic acid, (p-hydroxyphenyl)-
13.	19.047	324,899	0.31	2,5-dimethylfuran-3,4(2H,5H)-dione
14.	20.188	13,939,313	13.24	2-piperidinone
15.	23.400	600,490	0.57	indole
16.	23.687	361,406	0.34	succinimide
17.	25.105	901,064	0.86	benzeneacetic acid
18.	25.875	3,700,728	3.52	hydrocinnamic acid
Total	–	105,255,824	100.00	–

Fig. 3. Representative gas chromatography–mass spectrometry (GC–MS) total ion chromatograms (TICs) of the salivary volatile organic compound (VOC) profile

Results

A total of 110 subjects participated in the study, including 35 OSCC subjects (group 1), 35 OPMD subjects (group 2) and 40 healthy controls (group 3). The demographic characteristics of the subjects are summarized in Table 1.

Group 1 comprised 35 OSCC subjects: stage I – 4 (11.4%); stage II – 2 (5.7%); stage III –16 (45.7%); and stage IV – 13 (37.1%). With regard to the histopathological diagnosis, OSCC was well differentiated in 10 cases (28.6%), moderately in 20 (57.1%) and poorly in 5 subjects (14.3%). The buccal mucosa (both right and left) was the most common site of OSCC, accounting for 13 cases (37.1%), followed by the base and lateral border of the tongue in 8 (22.9%), the gingivobuccal sulcus in 4 (11.4%), the alveolus in 4 (11.4%), the retromolar trigone area in 3 (8.6%), the soft palate in 2 subjects (5.7%), and the upper lip in 1 patient (2.9%) (Table 2).

Group 2 comprised 35 OPMD subjects, including 12 (34.3%) with OL (6 homogeneous and 6 non-homogenous OL cases), 14 (40.0%) with OSF and 9 (25.7%) with OLP.

Most of the OL patients had a clinical staging of C1L1P1 – 4 (33.3%) and C2L1P1 – 4 (33.3%). Among the OSF patients, 6 (42.9%) were in grade 2 and grade 3 (in total 12), with 2 (14.3%) in grade 1 and no subjects in grade 4. The REU staging in OLP patients showed a varied distribution (Table 2).

Sample information

The GC–MS analysis of 110 salivary samples using the ZSM-5/PDMS hybrid film detected about 128 distinct VOCs. Amongst them, 25 VOCs were determined to be statistically significant in differentiating between the 3 groups. The major chemical classes of VOCs identified were organic acids (40%), alcohols (20%), ketones (16%), alkanes (8%), acid amides (8%), heterocyclic compounds (4%), and phenols (4%) (Fig. 4). The salivary VOC metabolomic profiles were further evaluated based on gender, age, the type of tobacco used, the pathological tumor (T), node (N) and metastasis (M) (pTNM) classification, and histopathological staging.

Table 1. Demographic characteristics of the study subjects ($N = 110$)

Characteristic		n	Group 1 ($n = 35$)	Group 2 ($n = 35$)	Group 3 ($n = 40$)
Gender	M	58	13 (37.1)	25 (71.4)	20 (50.0)
	F	52	22 (62.9)	10 (28.6)	20 (50.0)
Age [years]	21–30	13	1 (2.9)	2 (5.7)	10 (25.0)
	31–40	26	5 (14.3)	8 (22.8)	13 (32.5)
	41–50	34	10 (28.6)	10 (28.6)	14 (35.0)
	51–60	20	7 (20.0)	10 (28.6)	3 (7.5)
	61–70	17	12 (34.3)	5 (14.3)	0 (0.0)
Tobacco use (both smoked and SLT products)	current users	35	10 (28.6)	25 (71.4)	0 (0.0)
	ex-users	18	16 (45.7)	2 (5.7)	0 (0.0)
	non-users	57	9 (25.7)	8 (22.8)	40 (100)
Type of tobacco products used	smoked	5	4 (15.4)	1 (3.7)	–
	SLT	48	22 (84.6)	26 (96.3)	–
Habit duration [years]	1–10	10	6 (23.1)	4 (14.8)	–
	11–20	10	5 (19.2)	5 (18.5)	–
	21–30	27	9 (34.6)	18 (66.7)	–
	31–40	5	5 (19.2)	0 (0.0)	–
	41–50	1	1 (3.8)	0 (0.0)	–
Frequency of use [times/day]	2–4	30	14 (53.8)	16 (59.3)	–
	5–7	20	10 (38.5)	10 (37.0)	–
	8–10	3	2 (7.7)	1 (3.7)	–
Other habits	alcohol consumption	25	15 (42.9)	10 (28.6)	0 (0.0)
Comorbidities	hypertension	14	6 (17.1)	8 (22.9)	–
	diabetes mellitus	8	4 (11.4)	4 (11.4)	–
	both	7	3 (8.6)	4 (11.4)	–
	other	6	4 (11.4)	2 (5.7)	–
	none	35	18 (51.4)	17 (48.6)	–

Data presented as number (percentage) (n (%)).
Groups: 1 – oral squamous cell carcinoma (OSCC) subjects; 2 – oral potentially malignant disorder (OPMD) subjects; 3 – healthy controls. SLT – smokeless tobacco; M – male; F – female.

1114

S.P. Kunjumon et al. Potential diagnostic markers of oral cancer

Table 2. Clinical data of the study subjects (*N* = 110)

Data			*n*	Group 1 (*n* = 35)	Group 2 (*n* = 35)	Group 3 (*n* = 40)
Diagnosis	OSCC		35	35 (100.0)	–	–
	OL		12	–	12 (34.3)	–
	OSF		14	–	14 (40.0)	–
	OLP		9	–	9 (25.7)	–
Staging	OSCC pTNM – AJCC (2017)	stage I	4	4 (11.4)	–	–
		stage II	2	2 (5.7)	–	–
		stage III	16	16 (45.7)	–	–
		stage IV	13	13 (37.1)	–	–
	OL[9]	C1L1P0	2	–	2 (16.7)	–
		C1L1P1	4	–	4 (33.3)	–
		C1L2P1	1	–	1 (8.3)	–
		C2L1P0	1	–	1 (8.3)	–
		C2L1P1	4	–	4 (33.3)	–
	OSF[10]	grade 1	2	–	2 (14.3)	–
		grade 2	6	–	6 (42.9)	–
		grade 3	6	–	6 (42.9)	–
		grade 4	0	–	0 (0.0)	–
	OLP[11] (REU staging)	R1E3U0	1	–	1 (11.1)	–
		R1E3U3	1	–	1 (11.1)	–
		R1E6U0	1	–	1 (11.1)	–
		R1E6U3	1	–	1 (11.1)	–
		R1E6U6	1	–	1 (11.1)	–
		R1E6U9	1	–	1 (11.1)	–
		R2E3U0	1	–	1 (11.1)	–
		R2E6U1	1	–	1 (11.1)	–
		R6E8U5	1	–	1 (11.1)	–
Histopathological diagnosis (OSCC)	well differentiated		10	10 (28.6)	–	–
	moderately differentiated		20	20 (57.1)	–	–
	poorly differentiated		5	5 (14.3)	–	–
Site of OSCC	buccal mucosa (right and left)		13	13 (37.1)	–	–
	base and lateral border of the tongue		8	8 (22.9)	–	–
	gingivobuccal sulcus (right)		4	4 (11.4)	–	–
	alveolus		4	4 (11.4)	–	–
	retromolar trigone (left)		3	3 (8.6)	–	–
	soft palate		2	2 (5.7)	–	–
	lip (upper)		1	1 (2.9)	–	–

Data presented as *n* (%).
Groups: 1 – oral squamous cell carcinoma (OSCC) subjects; 2 – oral potentially malignant disorder (OPMD) subjects; 3 – healthy controls. OL– oral leukoplakia; OSF – oral submucous fibrosis; OLP – oral lichen planus; pTNM classification – pathological tumor (T), node (N) and metastasis (M); AJCC – American Joint Committee on Cancer.

Statistical analysis

VOC profiles based on gender

In groups 1, 2 and 3, the VOC profiles were compared according to gender. Six metabolites were statistically significant ($p \leq 0.05$) in group 1, with 5 being more common in males than females. Organic acids (50.0%), alcohols (16.6%), ketones (16.6%), and acid amides (16.6%) were the chemical classes of VOCs identified in the OSCC subjects (Fig. 5). Group 2 showed 3 VOCs that were statistically significantly more common in females as compared to males. Organic acids (100.0%) were the only VOCs found in group 2 (Fig. 6). There were no significant differences in VOCs between genders in group 3.

VOC profiles based on age

Upon comparing the VOC profiles between different age groups, group 1 revealed 3 statistically significant classes of compounds, i.e., organic acids (33.3%), alcohols (33.3%) and ketones (33.3%), which were all more common in the 61–70 age group (Fig. 7), whereas group 2 also revealed 3 significant compounds, i.e., organic acids (33.3%), phenols (33.3%) and monosaccharides (33.3%), which were higher in the 41–50-year and 51–60-year age

groups (Fig. 8). However, in group 3, no significant differences in VOCs were found between the age groups.

VOC profiles based on the type of tobacco used

The VOC profiles of the users of smoked and SLT products were compared, and 15 compounds were found to be statistically significant ($p \leq 0.05$), with organic acids (75.0%) and esters (25.0%) being most prevalent in SLT users. Smokers had a mixture of organic acids (54.5%), alcohols (18.1%), amines (9.0%), ethers (9.0%), and nitriles (9.0%) (Fig. 9).

Comparison of VOCs based on pTNM staging in group 1 (OSCC)

When comparing the VOC profiles based on the pTNM staging, 12 VOCs were determined as statistically significant ($p \leq 0.05$). Organic acids, ketones, acid amides, ethers, and aldehydes were the predominant classes of the VOCs identified (Fig. 10).


Fig. 4. Relative distribution of volatile organic compounds (VOCs) according to the chemical class


Fig. 5. Distribution of volatile organic compounds (VOCs) based on gender in oral squamous cell carcinoma (OSCC) subjects


Fig. 7. Distribution of volatile organic compounds (VOCs) based on age in oral squamous cell carcinoma (OSCC) subjects

Fig. 6. Distribution of volatile organic compounds (VOCs) based on gender in oral potentially malignant disorder (OPMD) subjects


Fig. 8. Distribution of volatile organic compounds (VOCs) based on age in oral potentially malignant disorder (OPMD) subjects

Comparison of VOCs based on histopathological staging in group 1 (OSCC)

Examining the VOC profiles with regard to the 3 histological types of OSCC, 11 VOCs were found to be statisti-

cally significant ($p \leq 0.05$; odds ratio (OR) ≥ 1). Organic acids, ketones, acid amides, ethers, and aldehydes were identified as the predominant classes of VOCs (Fig. 11).


Fig. 9. Distribution of volatile organic compounds (VOCs) based on the type of tobacco used


Fig. 10. Distribution of volatile organic compounds (VOCs) based on the pTNM staging in oral squamous cell carcinoma (OSCC) subjects


Fig. 11. Distribution of volatile organic compounds (VOCs) based on the histopathological staging in oral squamous cell carcinoma (OSCC) subjects

Discussion

The present study investigated the human salivary volatile metabolome, which might prove to be an accurate and non-invasive tool for distinguishing between OSCC and OPMD subjects, and healthy controls. The GC–MS analysis revealed 128 different VOCs. Amongst the 25 significant VOCs identified, the predominant chemical classes were organic acids (40%), alcohols (20%), ketones (16%), alkanes (8%), acid amides (8%), heterocyclic compounds (4%), and phenols (4%) (Fig. 4). These analytes are clearly products of metabolic processes, i.e., they are endogenous metabolites that remain unaffected by daily activities or environmental conditions.

Although many volatile compounds might be easily detected in salivary samples, they are still influenced by various confounding factors, such as gender, age, diet, smoking, and certain medications. Also, a large number of VOCs in healthy subjects originate from the breakdown of food by normal intestinal flora and they are not indicative of any disease. The VOC profile may vary depending on gender, age, diet, physiological and nutritional status, and habits (alcohol consumption or smoking); therefore, VOCs could be considered as the "odor fingerprint" of individuals.[12] In the present study, the OSCC group revealed more males with statistically significant levels of organic acids, alcohols and ketones associated with oxidative stress (Fig. 5).

The fact that OSCC is more frequent in men than women, largely owing to their higher intake of alcohol and tobacco use, justified the higher level of these metabolites in males. In contrast to the VOC profile in the OSCC group, the OPMD subjects showed 3 significant organic acids with statistically significantly higher levels in females than males (Fig. 6). This finding is in accordance with a systematic review by Jia et al., which suggested that gender also influenced the breath VOC profile, with alkenes like isoprene and several other VOCs found to be gender-specific.[12] However, another study by Dragonieri et al. concluded that gender and age did not seem to affect the overall profile of the exhaled VOCs measured by an e-nose device.[13]

Metabolic reprogramming in OC is not yet fully elucidated, and therefore, the investigation of metabolic alterations is crucial for detecting novel diagnostic biomarkers and understanding the disease progression. In a couple of studies, saliva was used to unveil the metabolomic signature of OSCC. Studies have sought to identify salivary metabolite biomarkers that would discriminate OSCC subjects from healthy controls.[14] In the present study, the salivary VOC profiles obtained from individuals with OSCC and OPMDs were compared with regard to each other and healthy controls. Twenty-five VOCs were found significant between the OSCC subjects, the OPMD subjects and the healthy controls (Tables 3–6).

Table 3. Distribution of volatile organic compounds (VOCs) among the oral squamous cell carcinoma (OSCC), oral potentially malignant disorder (OPMD) and healthy subjects (based on the *p*-value)

No.	VOC class	VOCs	Group 1	Group 2	Group 3	*p*-value
1.	organic acids	butanoic acid	77.10%	74.3%	25.0%	0.001*
		pentanoic acid, 4-methyl-	40.0%	20.0%	2.5%	0.001*
		formic acid	11.4%	0.0%	2.5%	0.053*
		benzeneacetic acid	11.4%	20.0%	0.0%	0.015*
		phosphonic acid	20.0%	0.0%	12.5%	0.025*
		mercaptoacetic acid	8.6%	28.6%	10.0%	0.034*
		2-butenoic acid	0.0%	8.6%	0.0%	0.037*
		5-methylhexanoic acid	0.0%	8.6%	0.0%	0.037*
2.	alcohols	1,2-propanediol	8.6%	0.0%	0.0%	0.037*
		1-tridecanol	0.0%	0.0%	15.0%	0.004*
		propylene glycol	20.0%	28.6%	0.0%	0.002*
		3-furanmethanol	14.3%	8.6%	0.0%	0.056*
3.	ketones	2-propanone, 1-hydroxy-	48.6%	25.7%	2.5%	0.001*
		2-hydroxy-gamma-butyrolactone	28.6%	14.3%	2.5%	0.006*
		1,2-cyclopentanedione	20.0%	8.6%	0.0%	0.010*
		acetoin	34.3%	54.3%	10.0%	0.001*
4.	alkanes	butane, 1,4-bis(9,10-dihydro-9-methylanthracen-10-yl)-	11.4%	0.0%	2.5%	0.053*
		1-chloro-dodecane	0.0%	8.6%	30.0%	0.001*
5.	acid amides	propanamide, 2-hydroxy-	8.6%	0.0%	0.0%	0.037*
6.	heterocyclic compounds	indole	2.9%	14.3%	0.0%	0.018*
7.	phenols	phenol	11.4%	40.0%	5.0%	0.001*

Groups: 1 – oral squamous cell carcinoma (OSCC) subjects; 2 – oral potentially malignant disorder (OPMD) subjects; 3 – healthy controls. * statistically significant; red – significant VOCs in the OSCC patients; blue – significant VOCs in the OPMD patients; green – significant VOCs in the healthy controls.

Table 4. Distribution of volatile organic compounds (VOCs) among the oral squamous cell carcinoma (OSCC) and oral potentially malignant disorder (OPMD) subjects (based on the *p*-value and the odds ratio (*OR*))

No.	VOC class	VOCs	Group 1	Group 2	*OR*	*p*-value
1.	organic acids	butanoic acid	77.10%	74.3%	0.780	1.168
		phosphonic acid	20.0%	0.0%	0.000	0.005*
		mercaptoacetic acid	8.6%	28.6%	0.234	0.031*
		formic acid	11.4%	0.0%	0.000	0.039*
2.	alcohols	2-furanmethanol	25.7%	14.3%	2.077	0.232
		3-furanmethanol	14.3%	8.6%	1.778	0.452
3.	ketones	**2-propanone, 1-hydroxy-**	48.6%	25.7%	2.728	0.048*
		2-hydroxy-gamma-butyrolactone	28.6%	14.3%	2.400	0.145
		2,5-dimethylfuran-3,4(2H,5H)-dione	28.6%	25.7%	1.156	0.788
		1,2-cyclopentanedione	20.0%	8.6%	2.667	0.172
4.	alkanes	**butane, 1,4-bis(9,10-dihydro-9-methylanthracen-10-yl)-**	11.4%	0.0%	4.242	0.039*
5.	acid amides	propanediamide	20.0%	14.3%	1.500	0.526
6.	phenols	**phenol**	11.4%	40.0%	0.194	0.006*
7.	esters	diethyl phtalate	11.4%	8.6%	1.376	0.690

Groups: 1 – oral squamous cell carcinoma (OSCC) subjects; 2 – oral potentially malignant disorder (OPMD) subjects. * statistically significant; **bold** – significant VOCs.

Table 5. Distribution of volatile organic compounds (VOCs) among the oral potentially malignant disorder (OPMD) and healthy subjects (based on the *p*-value and the odds ratio (*OR*))

No.	VOC class	VOCs	Group 2	Group 3	*OR*	*p*-value
1.	organic acids	**mercaptoacetic acid**	28.6%	10.0%	3.600	0.039*
		pentanoic acid, 3-methyl-	2.9%	2.5%	1.140	0.924
		propanoic acid, 2-methyl-	62.9%	37.5%	2.820	0.028*
		benzeneacetic acid	20.0%	0.0%	0.000	0.003*
		butanoic acid, 3-methyl-	31.4%	22.5%	1.570	0.383
		2,6-dihydroxybenzoic acid	17.1%	10.0%	1.860	0.364
		heptanoic acid	14.3%	7.5%	2.050	0.342
		boric acid	2.9%	2.5%	1.140	0.924
		methanesulfonylacetic acid	5.7%	2.5%	2.360	0.479
		butanoic acid, 2-methyl-	20.0%	12.5%	1.750	0.377
		3-hydroxy-3-phenylpropionic acid	8.6%	0.0%	0.000	0.059*
		5-methylhexanoic acid	8.6%	0.0%	0.000	0.059*
		octanoic acid	2.9%	2.5%	1.140	0.924
		mandelic acid	5.7%	2.5%	2.360	0.479
		2-butenoic acid	8.6%	0.0%	0.000	0.059*
2.	alcohols	2-furanmethanol	14.3%	10.0%	2.077	0.232
		2,3-butanediol	28.6%	10%	1.500	0.569
		propylene glycol	28.6%	0.0%	0.000	0.001*
		1-dodecanol	5.7%	2.5%	2.360	0.479
3.	ketones	**acetoin**	54.3%	10.0%	10.680	<0.001*
		2-piperidinone	94.3%	87.5%	2.350	0.314
		2,5-dimethylfuran-3,4(2H,5H)-dione	25.7%	10.0%	3.110	0.073
4.	acid amides	acetamide	88.6%	70.0%	3.320	0.050*
5.	heterocyclic compounds	**indole**	14.3%	0.0%	0.000	0.013*
6.	phenols	**phenol**	40.0%	5.0%	12.66	<0.001*

Groups: 2 – oral potentially malignant disorder (OPMD) subjects; 3 – healthy controls. * statistically significant; blue – significant VOCs in the OPMD patients; **bold** – significant VOCs.

Table 6. Distribution of volatile organic compounds (VOCs) among the oral squamous cell carcinoma (OSCC) and healthy subjects (based on the *p*-value and the odds ratio (*OR*))

No.	VOC class	VOCs	Group 1	Group 3	*OR*	*p*-value
1.	organic acids	**butanoic acid**	77.10%	25.0%	10.125	<0.001*
		phosphonic acid	20.0%	12.5%	1.750	0.377
		pentanoic acid, 3-methyl-	2.9%	2.5%	1.147	0.924
		formic acid	11.4%	2.5%	5.032	0.122
		pentanoic acid, 4-methyl-	40.0%	2.5%	17.87	<0.001*
		pentanoic acid	14.3%	7.5%	2.056	0.342
2.	alcohols	**3-furanmethanol**	14.3%	0.0%	0.000	0.013*
		1,2-propanediol	8.6%	0.0%	0.000	0.059*
		1-tridecanol	0.0%	15.0%	0.000	0.017*
3.	ketones	**2-propanone, 1-hydroxy-**	48.6%	2.5%	36.830	<0.001*
		2-piperidinone	88.6%	87.5%	1.107	0.887
		2-hydroxy-gamma-butyrolactone	28.6%	2.5%	6.500	0.061
		2,5-dimethylfuran-3,4(2H,5H)-dione	28.6%	10.00%	3.600	0.039*
		1,2-cyclopentanedione	20.0%	0.0%	0.000	0.059*
4.	alkanes	**1-chloro-dodecane**	0.0%	30.0%	0.000	<0.001*
		butane, 1,4-bis(9,10-dihydro-9-methylanthracen-10-yl)-	11.4%	2.5%	5.032	0.122
5.	acid amides	propanediamide	20.0%	15.0%	1.417	0.568
		propanamide, 2-hydroxy-	8.6%	0.0%	0.000	0.059*
6.	esters	diethyl phtalate	11.4%	5.0%	1.161	0.842
7.	aldehydes	2,5-dihydroxybenzaldehyde	2.9%	2.5%	1.147	0.924

Groups: 1 – oral squamous cell carcinoma (OSCC) subjects; 3 – healthy controls. * statistically significant; red – significant VOCs in the OSCC patients; **bold** – significant VOCs.

The OPMD VOC models derived from the metabolic analysis demonstrated good separation from OSCC and healthy controls, highlighting the diagnostic potential of this non-invasive analytical approach. Eleven VOCs were found to be differentially expressed in OPMDs as compared to OSCC and controls. The categories of OPMDs among the subjects of this study included OL (both homogenous and non-homogenous), SMF and OLP. Six acids, 1 alcohol, 1 ketone, 1 acid amide, 1 heterocyclic compound, and 1 phenol were the VOCs with the levels significantly higher amongst the OPMD subjects.

Organic acids, like benzeneacetic acid, mercaptoacetic acid, 2-butenoic acid, propanoic acid, 2-methyl-, 5-methylhexanoic acid, and 3-hydroxy-3-phenyl propionic acid, were found predominantly. It is known that propionibacteria, oral commensal bacteria, convert carbohydrates to short-chain fatty acids (SCFA), especially propanoic acid, through anaerobic metabolism. Propanoic acid can also be produced during metabolism and can be generated from propionyl-CoA, an end-product in the altered metabolism of the amino acids valine, isoleucine, threonine, and methionine, as well as odd-chain fatty acid oxidation and the degradation of cholesterol.[15] A similar alteration of both propionyl-CoA and amino acid metabolism is observed in OL.[16] In view of the above, the level of propanoic acid, 2 methyl- was higher in the OPMD group

as compared to controls in the present study. The results of this study are in agreement with those presented by Wei et al., who identified the amino acids valine and phenylalanine for distinguishing OL from OSCC.[17] Mercaptoacetic acid was seen in 66.7% of OL subjects. It is among substances that cause halitosis – volatile sulfur-containing compounds, such as hydrogen sulfide, methyl mercaptan and dimethyl sulfide, which in turn are associated with periodontitis. Given that more than 75% of the OPMD subjects had a history of tobacco use, this finding is justified. On the other hand, 2-butenoic acid increases glycolysis and elevates cancer cell growth through modulating the p53-dependent pathway in response to nutrition depletion, thereby making it a potential biomarker for malignant transformation. 5-methylhexanoic acid and 5-methylsalicylic acid were found in most of the OL and OLP patients; however, there are no reports indicating their role as biomarkers in OL and OLP.

Amongst alcohols, propylene glycol was found in most of the OPMD patients (28.6%). Propylene glycol is reportedly used as a humectant in tobacco products, and the majority of patients in this group had a history of tobacco use. In the ketonic group, acetoin was significantly present among OL patients. However, there is a lack of literature about these VOCs in OPMDs; the elevation of these compounds can be attributed to the tobacco use status of the

patients, as acetoin is an ingredient of tobacco products. Acid amides and heterocyclic compounds, like indole, were also observed. Although there are no previous studies on the role of acetamide as a VOC biomarker in OPMDs, an in-vitro study by Sakano et al. found that amidases, which catalyze the hydrolysis of the compounds containing an amide group, are widely distributed in mammalian organs.[18] Acetamide was hence proposed as a possible substrate for amidases to produce ultimate carcinogens. The heterocyclic VOC indole was elevated in the OPMD group, which supports a previous study by Ishikawa et al., who showed indole-3-acetate, which is the conjugate base of indole, as a significant volatile biomarker for OLP.[19]

Twelve VOCs had statistically significantly higher levels in the OSCC groups as compared to the OPMD and control group. Organic fatty acids (33.3%), ketones (33.3%), alcohols (16.6%), alkanes (8.3%), and acid amides (8.3%) were the major classes of VOCs noted in the OSCC subjects.

Lipogenesis appears to be enhanced during carcinogenesis in order to support the tumor demand for cell membrane constituents. Also, free fatty acids are important in cell signaling in neoplasms.[20] This may explain the elevated levels of acid VOCs in OSCC subjects in this study. Butanoic acid was seen to be highly significant ($p = 0.001$) among the acids. Butanoic acid is an extracellular metabolite from periodontopathic bacteria, thought to play an important role in the progression of periodontitis through its contribution to the destruction of gingival tissues and the modulation of local immunity at gingival sites.[21] In addition, it has been reported that butanoic acid promotes the migration of normal and neoplastic epithelial cells.[22] The percentage of patients with butanoic acid detected was observed to gradually increase from the healthy controls to OPMD and further to the OSCC group. Apart from butanoic acid, pentanoic acid, 4-methyl-, 3-furanmethanol, 2-propanone,1-hydroxy-, 2-hydroxy-gamma-butyrolactone, and 1,2-cyclopentanedione also followed a similar trend, giving these VOCs strong potential to serve as early biomarkers in OSCC. Formic acid (11.4%) is thought to be a breakdown product of formaldehyde, which is also a component of tobacco smoke. Considering that 4 out of 10 active tobacco users in the OSCC group were smokers, it might be the reason for its occurrence in addition to its formation in cancer metabolism.

2-propanone, 1-hydroxy- was found to be significantly elevated amongst the group of ketones ($p = 0.001$) in comparison with both OPMD and healthy controls, which is in accordance with the study by Shigeyama et al., who dealt with the identification of salivary VOCs in oral cancer.[23] Ketones may function as chemoattractants and stimulate the migration of epithelial cancer cells, promoting primary tumor growth.[24] Ketone production is also linked to greater fatty acid oxidation rates, which have been reported in numerous malignancies. Cancer cells also exhibit altered glucose metabolism known as the Warburg effect, in which the production of their energy shifts from the Krebs cycle to glycolysis, which could explain the appearance of ketonic VOCs in this study. However, as the concentration of ketones in human fluids or breath fluctuates with certain activities, such as fasting, exercising and eating, some experts advise against using ketones as biomarkers.[25] Alcohols were also found in most of the OSCC patients, possibly due to the action of cytochrome P450 enzymes, which hydroxylate the lipid peroxidation biomarkers to produce alcohols. Phillips et al. published an article in 1999 identifying 22 VOCs in the exhaled breath of patients with lung cancer, 15 of which were alkanes.[26] Similarly, we found increased butane, 1,4-bis(9,10-dihydro-9-methylanthracen-10-yl)- levels, an alkane to be statistically significant ($p = 0.053$). The origin of this compound is related to oxidative stress; it is mainly formed during the lipid peroxidation of PUFA constituents of biological membranes, leading to the degradation of phospholipids and, eventually, cellular deterioration.[27] It is thought by some researchers to be a secondary product of oxidative stress[27]; however, others disagree with this hypothesis.[28] In addition, acid amides were also found to be significantly high ($p = 0.037$) in the OSCC group, thereby representing a strong biomarker for OSCC.

When comparing the VOC profiles between the OSCC and OPMD patients, it was the revealed that the salivary metabolites had the potential to discriminate OSCC from OPMD patients. Among the 14 identified metabolites, 6 compounds displayed statistically significant differences between both groups ($p \leq 0.05$) (Table 4).

The observed chemical classes of VOCs were acids, ketones and alkanes. Phosphonic acid, formic acid, 2-propanone, 1-hydroxy-, and butane, 1,4-bis(9,10-dihydro-9-methylanthracen-10-yl)- were the differentially expressed VOCs in OSCC in comparison with OPMDs. Except for mercaptoacetic acid and phenol, all metabolites were decreased in OPMDs as compared to OSCC. These up- and downregulations of metabolites may be due to the involvement of metabolites in different metabolic pathways simultaneously.[29] Periodontitis is also independently associated with OPMDs.[30] This link between periodontitis and OPMDs may explain the occurrence of mercaptoacetic acid and phenol in the OPMD patients, and their strong distinction as a volatile biomarker from OSCC.

Ten VOCs were found to be statistically significant in the comparison between OSCC and healthy controls (Table 6). There were 2 acids, 3 alcohols, 3 ketones, and 2 alkanes found. In addition to butanoic acid, pentanoic acid, 4-methyl- was the most significant VOC noted ($p > 0.001$) in OSCC patients. The findings of the present study are consistent with the previous research reporting elevated levels of branched-chain fatty acids in cancer-related volatilomic profiles.[31] The levels of 2 alcohols were found to be higher in the OSCC group, which could

be attributed to the cytochrome P450 enzymatic action, while 1 alcohol – 1-tridecanol, which is a flavoring and fragrance agent, was observed in only 15% of healthy controls in comparison with OSCC patients (0%), and hence was eliminated as a biomarker for OSCC. In addition to this, 1-chloro-dodecane, which is an alkane, was also eliminated as a biomarker for OSCC, as it was present in only 30% of healthy controls and completely absent in OSCC patients.

The remaining VOCs illustrated a rise amongst the OSCC group of patients, although they depicted relatively low statistical significance. Although not statistically significant, 2,5-dihydroxybenzaldehyde ($OR > 1$) was also observed in 2.9% of OSCC subjects. Aldehydes are generated as intermediates in cytotoxic processes during signal transduction, genetic regulation or cellular proliferation through alcohol metabolism, the reduction of hydroperoxide by cytochrome P450 as a secondary product of lipid peroxidation and the detoxification processes related to smoking. In the particular case of cancer, previous studies reported an increment in the activity of aldehyde dehydrogenases (ALDHs), with cancer cell propagation resulting in the growth and proliferation of tumor cells, thereby implying an increase in the concentration of aldehydes in blood and saliva. Increased aldehyde production in cancer patients may be due to changes in membrane lipid composition and increased oxidative stress in tumor cells. Furthermore, increased levels of certain unsaturated fatty acids in the membranes of tumor cells may increase the production of certain aldehydes through lipid peroxidation. Aldehyde dehydrogenases and alcohol dehydrogenases (ADHs) are two abundant enzyme groups in the human liver. Aldehydes can be irreversibly oxidized to carboxylic acids by ALDHs or reduced to their corresponding alcohols by ADHs, thereby establishing a relation with organic acids and alcohols in accordance with the VOCs obtained in this study.

The analysis of the VOC profiles based on the pTNM staging showed that 12 VOCs were statistically significant ($p ≤ 0.05$) (Fig. 10). The predominant classes of VOCs were organic acids, ketones, acid amides, ethers, and furans. Oxalic acid (25%), 4-hydroxybutyric acid hydrazide (25%), boronic acid (25%), and tridecanoic acid (25%) were the significantly elevated acids found during the early stages, and the ethers diisoamyl ether (25%) and mephenesin (25%) were elevated as well. In addition, ketones like dihydroxyacetone (25%), acid amides like isobutyramide (25%) and furanal derivates like 5-(hydroxymethyl)furfural (25%) were also observed to be distinctively higher in the early stages in comparison with the advanced stages. Diethyl phthalate and 2-hydroxy-gamma-butyrolactone were significantly higher in all subjects with stage-II cancer (100%), providing a potential early biomarker. In addition to these, the acid amide propanamide, 2-hydroxy- (50%) was also observed equally often in both stage I and stage II. Diethyl phthalate and 2-hydroxy-gamma-butyro-

lactone were the only VOCs present in the advanced stages, i.e. stage III and stage IV. However, there have been no literature reports concerning the salivary VOCs based on the pTNM staging of OSCC till date, although similar studies have been done in breath volatilomics. Fu et al. found the exhaled breath concentration of 2-butanone significantly higher in patients with stage-I lung cancer in comparison with the advanced stages.[32] In contrast, Oguma et al. reported increased concentrations of cyclohexane and xylene in advanced lung cancer,[33] which does not agree with the results of the present. In another study, Corradi et al. showed that although lung cancer patients had higher levels of ethylbenzene in their breath, the difference between early-stage lung cancer patients and control subjects was less pronounced.[34] Peled et al. analyzed breath samples using GC–MS; however, the analysis did not reveal any significant differences between early-stage and late-stage lung cancer, nor did it show any distinction among the sub-histological types.[35]

As the prognosis and treatment options are critically dependent on the histology of the cancer, the salivary volatilomic profile in the OSCC patients was also identified based on the histopathological staging. The obtained metabolomic profile is in agreement with the literature, which supports the correlation between the pTNM and histopathological staging. Ten VOCs were statistically significant ($p ≤ 0.05$) (Fig. 11). The main classes of VOCs were organic acids, ketones, acid amides, ethers, and furans. Oxalic acid (25%), boronic acid (25%) and tridecanoic acid (25%) were significant in the early histological stages. In addition, ketones like dihydroxyacetone (25%) and 1,2-cyclopentanedione (45%), acid amides like isobutyramide (25%), and furanal derivates like 5-(hydroxymethyl)furfural (25%) were also observed to be distinctively higher in the early stages in comparison with the advanced stages. Diethyl phthalate and 2-hydroxy-gamma-butyrolactone were the only VOCs present in the advanced stage, i.e., in poorly differentiated OSCC, corresponding to the pTNM stages III and IV. These VOC profiles can potentially serve as non-invasive prognostic biomarkers in OSCC. However, there is a dearth of studies in the literature related to the identification of salivary VOCs based on the histopathological staging of OSCC. Few other studies showed that the histopathological staging had no significant impact on VOCs.[34,35]

Conclusions

The present study proposes a salivary VOC-based metabolomic profiling approach for patients with OSCC and OPMDs, compared with healthy controls, to support the discovery of clinically relevant biomarkers with potential diagnostic, prognostic and therapeutic applications. The findings provide volatilomic insights into the salivary metabolite alterations associated with OSCC and

1122

S.P. Kunjumon et al. Potential diagnostic markers of oral cancer

OPMDs. Although similar classes of compounds were detected in both disease groups, individual VOC profiles showed distinct variations. Additionally, the VOC profiles demonstrated significant associations with gender, age, the type of tobacco use, the pTNM classification, and the histopathological staging. These VOCs may represent tumor-specific candidate biomarkers suitable for screening OSCC and OPMDs. However, larger-scale studies are required to validate these findings and establish standardized protocols for their clinical implementation.

Limitations and recommendations

Challenges include the strong influence of confounding factors, such as food consumption, medications, physical activity, comorbid non-cancer diseases, and the normal gut microbiota, all of which can alter the pattern of generated VOCs. Care must therefore be taken to minimize the impact of these factors. Another limitation is that the origin and biological sources of many VOCs remain unclear, necessitating further research to better understand the altered metabolic pathways associated with their production.

The study population was small; therefore, the findings should be considered preliminary, and future studies should include larger sample sizes. Identifying distinguishable VOC fingerprints or the chemical groups associated with different cancers may facilitate early detection, provide insights into the mechanisms underlying cancer development and progression, and ultimately enable the manipulation of the altered metabolic pathways. Furthermore, the development of a portable, sensor-based point-of-care device for VOC detection would be invaluable in clinical practice for early diagnosis, monitoring disease states and assessing post-therapy outcomes.

Ethics approval and consent to participate

Ethical clearance was obtained from the Ethics Committee for Human Trials of M.S. Ramaiah University of Applied Sciences, Bengaluru, India (No. EC-2020/PG/36). Informed written consent was obtained from patients and controls after explaining the nature of the study.

Data availability

The patient datasets used in the current study are confidential and cannot be shared.

Consent for publication

Not applicable.

Use of AI and AI-assisted technologies

Not applicable.

ORCID iDs

Sreekanth Puthuparambil Kunjumon
  https://orcid.org/0000-0002-4174-6306
Sujatha S. Reddy https://orcid.org/0000-0002-8648-2340
Pavan Kumar Tupakula https://orcid.org/0000-0001-8993-2725
Shwetha Venkataramana https://orcid.org/0000-0002-3752-572X
Haripriya Prathap https://orcid.org/0009-0003-5947-1683
Ruchika Chaudhary https://orcid.org/0000-0003-1354-2661
Vaishnavi Palanisamy https://orcid.org/0000-0002-6054-8145
Laipubam Fabina Sharma https://orcid.org/0000-0002-0935-2542

References

1. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Author correction: Head and neck squamous cell carcinoma. *Nat Rev Dis Primers*. 2023;9(1):4. doi:10.1038/s41572-023-00418-5

2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024;74(3):229–263. doi:10.3322/caac.21834

3. Gupta B, Ariyawardana A, Johnson NW. Oral cancer in India continues in epidemic proportions: Evidence base and policy initiatives. *Int Dent J*. 2013;63(1):12–25. doi:10.1111/j.1875-595x.2012.00131.x

4. Veluthattil AC, Sudha SP, Kandasamy S, Chakkalakkoombil SV. Effect of hypofractionated, palliative radiotherapy on quality of life in late-stage oral cavity cancer: A prospective clinical trial. *Indian J Palliat Care*. 2019;25(3):383–390. doi:10.4103/IJPC.IJPC_115_18

5. Nagi R, Reddy-Kantharaj YB, Rakesh N, Janardhan-Reddy S, Sahu S. Efficacy of light based detection systems for early detection of oral cancer and oral potentially malignant disorders: Systematic review. *Med Oral Patol Oral Cir Bucal*. 2016;21(4):e447–e455. doi:10.4317/medoral.21104

6. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell*. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013

7. Feinberg T, Herbig J, Kohl I, et al. Cancer metabolism: The volatile signature of glycolysis – in vitro model in lung cancer cells. *J Breath Res*. 2017;11(1):016008. doi:10.1088/1752-7163/aa51d6

8. Taware R, Taunk K, Pereira JA, et al. Volatilomic insight of head and neck cancer via the effects observed on saliva metabolites. *Sci Rep*. 2018;8(1):17725. doi:10.1038/s41598-018-35854-x

9. Van der Waal I. Oral leukoplakia; a proposal for simplification and consistency of the clinical classification and terminology. *Med Oral Patol Oral Cir Bucal*. 2019;24(6):e799–e803. doi:10.4317/medoral.23372

10. Passi D, Bhanot P, Kacker D, Chahal D, Atri M, Panwar Y. Oral submucous fibrosis: Newer proposed classification with critical updates in pathogenesis and management strategies. *Natl J Maxillofac Surg*. 2017;8(2):89–94. doi:10.4103/njms.NJMS_32_17

11. Piboonniyom SO, Treister N, Pitiphat W, Woo SB. Scoring system for monitoring oral lichenoid lesions: A preliminary study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2005;99(6):696–703. doi:10.1016/j.tripleo.2004.07.013

12. Jia Z, Patra A, Kutty VK, Venkatesan T. Critical review of volatile organic compound analysis in breath and in vitro cell culture for detection of lung cancer. *Metabolites*. 2019;9(3):52. doi:10.3390/metabo9030052

13. Dragonieri S, Quaranta VN, Carratu P, Ranieri T, Resta O. Influence of age and gender on the profile of exhaled volatile organic compounds analyzed by an electronic nose. *J Bras Pneumol*. 2016;42(2):143–145. doi:10.1590/S1806-37562015000000195

14. Ishikawa S, Sugimoto M, Kitabatake K, et al. Identification of salivary metabolomic biomarkers for oral cancer screening. *Sci Rep*. 2016;6:31520. doi:10.1038/srep31520

15. Andresen L, Hansen KA, Jensen H, et al. Propionic acid secreted from propionibacteria induces NKG2D ligand expression on human-activated T lymphocytes and cancer cells. *J Immunol*. 2009;183(2):897–906. doi:10.4049/jimmunol.0803014

16. Sridharan G, Ramani P, Patankar S. Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. *J Cancer Res Ther*. 2017;13(3):556–561. doi:10.4103/jcrt.JCRT_1233_16

17. Wei J, Xie G, Zhou Z, et al. Salivary metabolite signatures of oral cancer and leukoplakia. *Int J Cancer*. 2011;129(9):2207–2217. doi:10.1002/ijc.25881

18. Sakano K, Oikawa S, Murata M, Hiraku Y, Kojima N, Kawanishi S. Mechanism of metal-mediated DNA damage induced by metabolites of carcinogenic 2-nitropropane. *Mutat Res*. 2001;479(1–2):101–111. doi:10.1016/s0027-5107(01)00158-0

19. Ishikawa S, Sugimoto M, Edamatsu K, Sugano A, Kitabatake K, Iino M. Discrimination of oral squamous cell carcinoma from oral lichen planus by salivary metabolomics. *Oral Dis*. 2020;26(1):35–42. doi:10.1111/odi.13209

20. Monedeiro F, Monedeiro-Milanowski M, Zmysłowski H, De Martinis BS, Buszewski B, Evaluation of salivary VOC profile composition directed towards oral cancer and oral lesion assessment. *Clin Oral Investig*. 2021;25(7):4415–4430. doi:10.1007/s00784-020-03754-y

21. Ochiai K, Kurita-Ochiai T. Effects of butyric acid on the periodontal tissue. *Jpn Dent Sci Rev*. 2009;45(2):75–82. doi:10.1016/j.jdsr.2009.06.002

22. Wilson AJ, Gibson PR. Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. *Gastroenterology*. 1997;113(2):487–496. doi:10.1053/gast.1997.v113.pm9247468

23. Shigeyama H, Wang T, Ichinose M, Ansai T, Lee SW. Identification of volatile metabolites in human saliva from patients with oral squamous cell carcinoma via zeolite-based thin-film microextraction coupled with GC–MS. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2019;1104:49–58. doi:10.1016/j.jchromb.2018.11.002

24. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and lactate "fuel" tumor growth and metastasis. *Cell Cycle*. 2010;9(17):3506–3514. doi:10.4161/cc.9.17.12731

25. Smith D, Wang T, Spaněl P. On-line, simultaneous quantification of ethanol, some metabolites and water vapour in breath following the ingestion of alcohol. *Physiol Meas*. 2002;23(3):477–489. doi:10.1088/0967-3334/23/3/301

26. Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: A cross-sectional study. *Lancet*. 1999;353(9168):1930–1933. doi:10.1016/S0140-6736(98)07552-7

27. Phillips M, Cataneo RN, Cummin AR, et al. Detection of lung cancer with volatile markers in the breath. *Chest*. 2003;123(6):2115–2123. doi:10.1378/chest.123.6.2115

28. Hakim M, Broza YY, Barash O, et al. Volatile organic compounds of lung cancer and possible biochemical pathways. *Chem Rev*. 2012;112(11):5949–5966. doi:10.1021/cr300174a

29. Musharraf SG, Shahid N, Ali Naqvi SM, Saleem M, Siddiqui AJ, Ali A. Metabolite profiling of preneoplastic and neoplastic lesions of oral cavity tissue samples revealed a biomarker pattern. *Sci Rep*. 2016;6:38985. doi:10.1038/srep38985

30. Bhat M, Bhat S, Roberts-Thomson K, Do LG. Is periodontitis independently associated with potentially malignant disorders of the oral cavity? *Asian Pac J Cancer Prev*. 2019;20(10):283–287. doi:10.31557/APJCP.2019.20.1.283

31. Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol*. 2013;11(7):868–875.e1–e3. doi:10.1016/j.cgh.2013.02.015

32. Fu XA, Li M, Knipp RJ, Nantz MH, Bousamra M. Noninvasive detection of lung cancer using exhaled breath. *Cancer Med*. 2014;3(1):174–181. doi:10.1002/cam4.162

33. Oguma T, Nagaoka T, Kurahashi M. Clinical contributions of exhaled volatile organic compounds in the diagnosis of lung cancer. *PLoS One*. 2017;12(4):e0174802. doi:10.1371/journal.pone.0174802

34. Corradi M, Poli D, Banda I, et al. Exhaled breath analysis in suspected cases of non-small-cell lung cancer: A cross-sectional study. *J Breath Res*. 2015;9(2):027101. doi:10.1088/1752-7155/9/2/027101

35. Peled N, Hakim M, Bunn Jr. PA, et al. Non-invasive breath analysis of pulmonary nodules. *J Thorac Oncol*. 2012;7(10):1528–1533. doi:10.1097/JTO.0b013e3182637d5f